Micro- and nanoparticulates.
OBJECTIVE
Pharmacotherapeutics has begun to play an increasingly important role in the management of patients with neovascular age-related macular degeneration (AMD). Because micro- and nano-particulates are currently being evaluated as a potential drug-delivery option for AMD patients, the purpose of this analysis was to describe how micro- and nano-particulates have been used experimentally and what their potential clinical applications may be.


RESULTS
Micro- and nano-particulates have been used primarily on a pre-clinical basis as new drug-delivery devices in experimental models of neovascular AMD.


CONCLUSIONS
It is likely that micro- and nano-particulates will become an important component of targeted clinical pharmacotherapeutics in patients with neovascular AMD.
Moshfeghi
Andrew A
AA
Bascom Palmer Eye Institute, 900 NW 17th St Miami, FL 33136, USA. amoshfeghi@med.miami.edu
Peyman
Gholam A
GA
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D019819:Budesonide / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D003692:Delayed-Action Preparations / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems / Q000379:methods; D005128:Eye Diseases / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D008863:Microspheres; D049329:Nanostructures / Q000737:chemistry*; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D019819:Budesonide